2025.05.24本文字数:1603,阅读时长大约4.1分钟导读:基因编辑企业Prime Medicine在2025年5月19日股价暴跌19%,因公司调整战略,聚焦肝脏遗传病和囊性纤维化项目,同时裁员25%并更换CEO。其AATD项目面临诸多挑战,市场前景不明朗,公司未来充满不确定性。在2025年5月19日,备受瞩目的基因编辑治疗企业Prime Medicine在开盘之后股价出现了19%的大幅...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.